International treatment guidelines for hepatitis B emphasize alanine aminotransferase (ALT) and serum HBV DNA thresholds, but strict adherence to these markers might lead to missed opportunities in some patients with acquisition in early life. Clinical trials have used improvement in liver histology, rate of hepatitis B e antigen seroconversion, and sustained HBV DNA suppression as primary end points. Th ese are potentially short-term end points because HBV infection cannot be eradicated and delayed relapses might occur. Th e closest end point to a clinical cure of disease is the loss of hepatitis B surface antigen (HBsAg) . Th e ability of interferon to stimulate the immune response of the host might explain the higher rate of early HBsAg clearance when compared with nucleoside analogues. Early studies suggest that combination therapy with interferon and long-term treatment with nucleoside analogues might lead to an even higher rate of HBsAg seroconversion. Measuring HbsAg concentration during therapy might provide an early indication that a durable virological response, including HBsAg clearance, is likely to occur. Th us far, this has been best studied using interferon. Th e relationship of this phenomenon to viral genotype will be discussed. Th ere is a need for more fl exible on-treatment criteria for hepatitis B. HBsAg clearance remains the best therapeutic end point, but is not readily achievable with current treatments. Future treatment paradigms should take into account the duration as well as the extent of viraemia, place less reliance on the ALT level to indicate the extent of liver injury and consider the possibility that maintenance therapy can prevent liver disease complications.
BREAST CANCER RESEARCH AND TREATMENT
Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials We sought to determine if an association exists between age and capecitabine efficacy among patients with metastatic breast cancer (MBC). Pooled analysis of five phase II or III registration trials of capecitabine 2,500-2,510 mg/m 2 /day for 2 weeks and 1 week off, or combination therapy was performed. Four trials enrolled patients previously exposed to other chemotherapy, generally a taxane. Of 570 patients, 193 (34%) were 18-49 years old, 246 (43%) were 50-64, and 131 (23%) were ≥65. Median average daily dose was 2,067 mg/m 2 in the 18-to 49-year-old group and 2,105 mg/m 2 in the 50-64 and ≥65 year groups. Overall survival (OS) in all groups was similar by log-rank test for the individual trials (P = 0.71-0.95) and Cox regression of the pooled trials. Univariate analysis demonstrated no difference in clinical benefit or objective response between groups. Treatment failure analysis showed 283 (50%) patients experienced progressive disease, while 114 (20%) withdrew for safety. Serious adverse events (AEs) occurred in 71 (36.8%), 85 (34.6%), and 59 (45.0%) patients in the 18-49, 50-64, and ≥65 years groups, respectively. There was no statistically significant association between age and OS, clinical benefit, or objective response in patients with MBC treated with capecitabine. Frequency of AEs and serious AEs was not related to age at treatment, although women ≥65 years were more likely to withdraw from treatment because of an AE than younger women.
CLINICS IN DERMATOLOGY

How real is senescent alopecia? A histopathologic approach
Whiting DA Clin Dermatol 2011;29(1):49-53. Reprinted with permission from Elsevier.
Senescent alopecia was originally thought to aff ect people aged 50 years or older with no family history or evidence of pattern balding. It was described as a diff use thinning involving the whole scalp due to a steady decrease in thick terminal hairs, but without evidence of increased miniaturization. Senescent alopecia is not a primary diagnosis in this clinic. Most possible examples of it are assumed to be androgenetic or diff use alopecia. In the study reported here, horizontal sections of 2149 scalp specimens from individuals with male and female pattern and diff use alopecia, as well as from normal controls, were examined, and their follicular counts were recorded and sorted into decades. Th e decade of 20 to 29 years contained a signifi cant number of patients and was used for baseline follicular counts for comparison with all succeeding decades up to age 99 years. A reduction of 15% below baseline was considered signifi cant. In 10.6% of patients with male pattern alopecia, the age of onset of a signifi cant reduction in follicular counts was 50 years; in 5.7% of patients with female pattern alopecia it was 70 years, and in 2.0% of patients with diff use alopecia it was 80 years. Th ese data suggest that most cases of signifi cant hair loss in the elderly are androgen driven. Th e few patients with deteriorating diff use alopecia may be the exception. Th e study concluded that old age is not a signifi cant cause of hair loss.
CLINICAL NUCLEAR MEDICINE
Visualization of discrete sacral foramina as an ancillary sign of superscan Objectives: Th e purpose of this study was to determine if visualization of discrete sacral foramina on bone scintigraphy can be used as an adjunct criterion supportive of a superscan diagnosis.
Methods: Th e Radiology Information System at our institution was queried for all bone scintigraphy reports, during July 1999 to July 2009, containing the words/phrases: normal bone scan, normal bone scintigraphy, superscan, or diff use osseous metastatic disease. Th e fi nal study group consisted of 22 normal studies and 8 superscans. All studies were reviewed by 2 nuclear medicine physicians who rated the examinations on a numeric scale of bone-to-soft tissue activity, whether they would classify the study as a superscan (based on previously published criteria), whether sacral foramina were visualized, and, if so, how many?
Results: Of the 22 normal studies, no distinct sacral foramen was visualized in 17 cases. Of the 8 superscan patients, 1 patient demonstrated 8 foramina, 4 patients demonstrated 4 foramina, 1 patient demonstrated 3 foramina, and 2 patients demonstrated none. Th ere was a statistically signifi cant diff erence between the normal and superscan groups (P < 0.0017). Based on statistical analysis, it was determined that visualizing at least 3 distinct sacral foramina could be used as an ancillary fi nding to support the diagnosis of superscan.
Conclusions: Th e ability to clearly visualize at least 3 sacral foramina is a statistically signifi cant fi nding that may be useful as an ancillary criterion to diff erentiate normal bone scintigraphy from a superscan.
INTERNATIONAL JOURNAL OF CANCER
Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells Worldwide oral squamous cell carcinoma (OSCC) accounts for more than 100,000 deaths each year. Chronic infl ammation constitutes one of the key risk factors for OSCC. Accumulating evidence suggests that aberrant DNA methylation may contribute to OSCC tumorigenesis. Th is study investigated whether chronic infl ammation alters DNA methylation and expression of cancerassociated genes in OSCC. We established an in vitro model of interleukin (IL)-6 mediating chronic infl ammation in OSCC cell lines. Th ereafter, we measured the ability of IL-6 to induce global hypomethylation of long interspersed nuclear element-1 (LINE-1) sequences, as well as CpG methylation changes using multiple methodologies including quantitative pyrosequencing, methylation-specifi c multiplex ligation-dependent probe amplifi cation and sensitive melting analysis after real-time-methylation-specifi c polymerase chain reaction (PCR). Gene expression was investigated by quantitative reverse transcriptase-PCR. IL-6 induced signifi cant global LINE-1 hypomethylation (P = 0.016) in our in vitro model of infl ammatory stress in OSCC cell lines. Simultaneously, IL-6 induced CpG promoter methylation changes in several important putative tumor suppressor genes including CHFR, GATA5 and PAX6. Methylation changes correlated inversely with the changes in the expression of corresponding genes. Our results indicate that IL-6-induced infl ammation promotes tumorigenesis in the oral cavity by altering global LINE-1 hypomethylation. In addition, concurrent hypermethylation of multiple tumor suppressor genes by IL-6 suggests that epigenetic gene silencing may be an important consequence of chronic infl ammation in the oral cavity. Th ese fi ndings have clinical relevance, as both methylation and infl ammation are suitable targets for developing novel preventive and therapeutic measures. Objective: To determine the impact of a standardized heart failure order set on mortality, readmission, and quality and costs of care.
Design: Observational study.
Setting: Eight acute care hospitals and two specialty heart hospitals.
Participants: All adults (>18 years) discharged from one of the included hospitals between December 2007 and March 2009 with a diagnosis of heart failure, who had not undergone heart transplant, did not have a left ventricular assistive device, and with a length of stay of 120 or less days.
Interventions:
A standardized heart failure order set was developed internally, with content driven by the prevailing American College of Cardiology/American Heart Association clinical practice guidelines, and deployed systemwide via an intranet physician portal.
Main outcome measures:
Publicly reported process of care measures, in-patient mortality, 30-day mortality, 30-day readmission, length of stay, and direct cost of care were compared for heart failure patients treated with and without the order set.
Results: Order set use reached 73.1% in March 2009. After propensity score adjustment, order set use was associated with signifi cantly increased core measures compliance [odds ratio (95% confi dence interval) = 1.51(1.08; 2.12)] and reduced in-patient mortality [odds ratio (95% confi dence interval) = 0.49(0.28; 0.88)]. Reductions in 30-day mortality and readmission approached signifi cance. Direct costs for initial admissions alone and in combination with readmissions were signifi cantly lower with order set use.
Conclusions: Implementing an evidence-based standardized order set may help improve outcomes, reduce costs of care and increase adherence to evidence-based processes of care. In the search for a therapeutic HIV-1 vaccine, we describe herein the development of a monocyte-derived dendritic cell (DC) vaccine loaded with a mixture of HIV-1-antigen lipopeptides (ANRS HIV-LIPO-5 vaccine). LIPO-5 is comprised of fi ve HIV-1-antigen peptides (Gag 17-35 , Gag 253-284 , Nef 66-97 , Nef 116-145 , and Pol 325-355 ), each covalently linked to a palmitoyl-lysylamide moiety. Monocytes enriched from HIV-1-infected highly active antiretroviral therapy (HAART)-treated patients were cultured for three days with granulocyte-macrophage colony-stimulating factor and alpha-interferon. At day 2, the DCs were loaded with ANRS HIV-LIPO-5 vaccine, activated with lipopolysaccharide, harvested at day 3 and frozen. Flow cytometry analysis of thawed DC vaccines showed expression of DC diff erentiation markers: CD1b/c, CD14, HLA-DR, CD11c, co-stimulatory molecule CD80 and DC maturation marker CD83. DCs were capable of eliciting an HIV-1-antigen-specifi c response, as measured by expansion of autologous CD4 + and CD8 + T-cells. Th e expanded T-cells secreted gamma-IFN and interleukin (IL)-13, but not IL-10. Th e safety and immunogenicity of this DC vaccine are being evaluated in a Phase I/II clinical trial in chronically HIV-1-infected patients on HAART. Objective: Th e aim of the study was to identify which fall-risk tool is most accurate for assessing adults in the hospital setting.
JOURNAL OF IMMUNOLOGICAL METHODS
Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine
JOURNAL OF NURSING ADMINISTRATION
Meta-analysis of fall-risk tools in hospitalized adults
Background: Falls can have physical, emotional, social, and fi nancial consequences. Risk assessment aff ords the fi rst opportunity in prevention.
Methods: To standardize the use of a fall-risk tool across the Baylor Health Care System, nurse executives undertook a meta-analysis of published research on fall-risk assessment tools used with adult inpatients.
Results: Both random-eff ects and fi xed-eff ects models showed that Morse Fall Scale had signifi cantly higher sensitivity than St Th omas's Risk Assessment Tool (STRATIFY). Specifi city of Morse Fall Scale was signifi cantly lower than that of STRATIFY with the fi xed-eff ects model, but the random-eff ects model showed the opposite. Morse Fall Scale had a signifi cantly higher Youden index than STRATIFY with the fi xed-eff ects model (P = .001), but the result from randomeff ects model indicated no signifi cant diff erence (P = .117). Th e sensitivity, specifi city, and Youden index fell within the 95% confi dence intervals.
Conclusions: Meta-analysis is a useful methodology for evaluating current evidence when variation exists in the literature. In recent years, there has been a great increase in the number of cases of image-guided fi ducial marker placement for the purposes of stereotactic radiosurgery. At the authors' parent institution, a tertiary referral academic medical center, the placement of fi ducial markers has also been used for the purposes of localization before spine surgery. Given the reported prevalence of "wrong-site" surgical intervention documented in the medical literature, particularly involving spinal surgery, the neurosurgical department at the authors' institution has requested the expertise of interventional radiology for assistance in preoperative spine localization. Th erefore, there are medicolegal, medical cost, and patient care implications of image-guided fi ducial marker placement.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
Fiducial marker placement for intraoperative spine localization
MOVEMENT DISORDERS
Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis Clinical trials demonstrate that onabotulinumtoxinA reduces upper limb post-stroke spasticity, with therapeutic response infl uenced by injected dose. Individual studies provide limited insight regarding muscle group-specifi c dose-response relationships. Our objective was to characterize dose-response relationships between onabotulinumtoxinA and muscle tone in specifi c upper limb muscles. Individual patient data from seven multicenter, randomized, double-blind, placebocontrolled trials were pooled. Of 544 post-stroke patients enrolled, 362 received onabotulinumtoxinA and 182 received placebo, injected into the fl exor carpi radialis (FCR), fl exor carpi ulnaris (FCU), fl exor digitorum superfi cialis (FDS), fl exor digitorum profundus (FDP), and/or biceps brachii (BB). Ashworth Scale score change at week 6 (AshworthCBL) was the primary outcome measure for muscle tone. For a broader analysis of response, AshworthCBL/onabotulinum-toxinA dosage relationships were characterized using three techniques:
(1) AshworthCBL plotted as a function of onabotulinumtoxinA dose in Units (U) [dose-response curve]; (2) mean AshworthCBL per onabotulinumtoxinA dose depicting the responses seen with specifi c dose injection clusters/groups for each specifi c muscle group; and (3) onabotulinumtoxinA dose estimated to produce a mean 1-point decrease in AshworthCBL as an indicator of clinically meaningful benefi t of treatment. Increasing onabotulinumtoxinA doses produced greater AshworthCBLs (muscle tone improvements). Th e maximal week 6 response (E max ) model indicated a saturating dose-response relationship, with mean E max AshworthCBL values of -1.48, -1.48, -0.63, -0.77, and -0.61 in the FCR, FCU, FDS, FDP, and BB, respectively. OnabotulinumtoxinA doses estimated to produce a mean 1-point decrease in AshworthCBL were: 22. 5U, 18.4U, 66.3U, 42.5U in the FCR, FCU, FDS, and FDP, respectively, and not determinable in the BB. Th ese analyses demonstrate a saturating eff ect of greater muscle tone improvements with increasing onabotulinumtoxinA doses in post-stroke spasticity patients. Th ese fi ndings suggest potentially eff ective onabotulinumtoxinA doses in selected muscle groups in this study population. Background: Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition.
Methods:
We conducted an open-label, phase 2 study to compare the effi cacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1 and 8-with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11-every 21 days. Primary end points were the rate of clinical benefi t (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 months) and safety. Additional end points included the rate of objective response, progression-free survival, and overall survival.
Results
: Th e addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefi t from 34% to 56% (P = 0.01) and the rate of overall response from 32% to 52% (P = 0.02). Th e addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months (hazard ratio for progression, 0.59; P = 0.01) and the median overall survival from 7.7 months to 12.3 months (hazard ratio for death, 0.57; P = 0.01). Th e most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level. No signifi cant diff erence was seen between the two groups in the rate of adverse events.
Conclusions
: Th e addition of iniparib to chemotherapy improved the clinical benefi t and survival of patients with metastatic triple-negative breast cancer without signifi cantly increased toxic eff ects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted.
SURGERY FOR OBESITY AND RELATED DISEASES
Surgical weight loss >65 years old: is it worth the risk?
Willkomm CM, Fisher TL, Barnes GS, Kennedy CI, Kuhn JA Surg Obes Relat Dis 2010;6(5):491-496. Reprinted with permission from Elsevier.
Background: Weight loss surgery in patients >65 years old has been underused, secondary to the morbidity and mortality concerns of healthcare providers. Comparative outcomes analyses of this patient population have been lacking. Th e purpose of the present report was to evaluate the safety and outcome of gastric bypass in patients >65 years of age.
Methods: A prospective database was used to analyze the safety, operative morbidity, and outcome. All patients undergoing surgery since January 2005 were included.
Results: Th e analysis of 1474 patients demonstrated a greater operative risk profi le for patients >65 years (n = 100) compared with those <65 years old (n = 1374) related to sleep apnea (45% versus 34%), diabetes mellitus (65% versus 33%), and hypertension (81% versus 57%). Th e operative outcomes were similar for the 2 groups as determined by the operative time (70 versus 65 minutes), length of stay (1.97 versus 1.3 days), and 30-day readmission rate (6.0% versus 7.4%). Th e postoperative complication rates were low in the patients >65 years old (bleeding 1.0%, pulmonary 3.0%, cardiac 2.0%, wound 2.0%, and 30-day mortality rate 0%). Th e percentage of excess body weight loss in the gastric bypass patients was similar between the patients >65 years old and those >65 years old at 12 months (74.8% versus 77.8%) and 24 months (83.4% versus 78.5%).
Conclusion:
Our experience represents one of the largest series of laparoscopic gastric bypass in elderly patients. Th e data have demonstrated excellent outcomes compared with a younger population.
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